PMC:7594251 / 1608-1836
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T7 | 154-162 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 165-173 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T11156 | 194-196 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T11 | 104-108 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 20 | 154-164 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 21 | 165-173 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T15 | 25-121 | Sentence | denotes | We also summarize the advantages and limitations of the primary NMR methods in drug development. |
| T16 | 123-125 | Sentence | denotes | 1. |
| T17 | 126-138 | Sentence | denotes | Introduction |